Home > Riviste > Minerva Anestesiologica > Fascicoli precedenti > Articoli online first > Minerva Anestesiologica 2016 Nov 30

ULTIMO FASCICOLOMINERVA ANESTESIOLOGICA

Rivista di Anestesia, Rianimazione, Terapia Antalgica e Terapia Intensiva


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036


eTOC

 

Minerva Anestesiologica 2016 Nov 30

lingua: Inglese

Clinical indices and biomarkers for perioperative cardiac risk stratification: an update

Radmilo J. JANKOVIĆ 1, 2, Danica Z. MARKOVIĆ 2, Dušan T. SOKOLOVIĆ 3, Ivana ZDRAVKOVIĆ 4, Massimiliano SORBELLO 5

1 Department for Anesthesiology and Intensive Care, School of Medicine, University of Niš, Serbia; 2 Center for Anesthesiology and Reanimatology, Clinical Center of Niš, Serbia; 3 Department for Biochemistry, School of Medicine, University in Niš, Serbia; 4 Department for Anesthesiology and Reanimatology, Clinical Hospital Center ‘Zvezdara’, Belgrade, Serbia; 5 Anesthesia and Intensive Care, AOU Policlinico Vittorio Emanuele, Catania, Italy


PDF  ESTRATTI


European Society of Cardiology (ESC)/ European Society of Anesthesiology (ESA) highlighted that anesthesiologist has a leading role in perioperative cardiovascular assessment and management in the year of 2014. During cardiovascular assessment one can rely on cooperation of multi-disciplinary specialists like: other anesthesiologists, cardiologists and surgeons. For the purpose of precise systematization and decision making the Lee score or NSQUIP database can be used besides the traditionally used ASA score. Additional help is provided with specific palette of cardiac biomarkers like: cTnT, cTnI, CRP, NT-proBNP, BNP, etc. Biomarkers are considered to represent a foundation of Evidence Based Medicine and they help anesthesiologists in the decision-making process. They increase the possibilty to achieve the best clinical outcome for each patient. An ideal biomarker doesnt exist and therefore new research are currently being conducted with the aim to find and declare more specific biomarkers like H-FABP, miRNA, PAMP and hsTnT.

inizio pagina